NASDAQ:MRVI
Maravai Lifesciences Holdings, Inc.
Maravai Lifesciences Holdings, Inc.'s revenue fell 28.3% in fiscal 2025 to $185.7M while operating margin fell to −115.9%, its lowest in 7 years. Free cash flow was −$70.7M, −38.1% of revenue, and the diluted share count rose 4.7%.Summary generated from Maravai Lifesciences Holdings, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$185.7M
Revenue growth−28.3%
Revenue, 5-yr CAGR−8.1%
Gross margin18.3%
Operating margin−115.9%
Net margin−70.4%
ROIC−58.0%
Return on equity−48.6%
Debt / equity1.37
Free cash flow−$70.7M
FCF margin−38.1%
Share count change+4.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 799 | 883 | 289 | 259 | 186 |
| Operating income | 555 | 574 | −32 | −236 | −215 |
| Net income | 182 | 220 | −119 | −145 | −131 |
| Free cash flow | 354 | 519 | 61 | −22 | −71 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 4Insider transaction report
Oct 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KEntry into a material agreement
Jun 3, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026 - 8-KResults of operations and financial condition
May 7, 2026